- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 465179, 10 pages
Molecular Characterization and Clinical Impact of TMPRSS2-ERG Rearrangement on Prostate Cancer: Comparison between FISH and RT-PCR
1Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, C/Professor Beltrán Báguena 8, 46009 Valencia, Spain
2Department of Pathology, Fundación Instituto Valenciano de Oncología, C/Professor Beltrán Báguena 8, 46009 Valencia, Spain
3Department of Urology, Fundación Instituto Valenciano de Oncología, C/Professor Beltrán Báguena 8, 46009 Valencia, Spain
4Laboratori de Citogenètica Molecular, Servei de Patologia, GRETNHE, Programa de Recerca en Càncer, IMIM, Institut de Recerca del Hospital del Mar, Parc de Salut Mar, 08003 Barcelona, Spain
5Department of Pathology, Universitat de Valencia Estudi General, 46010 Valencia, Spain
Received 26 December 2012; Accepted 30 April 2013
Academic Editor: Sachidanand Pandey
Copyright © 2013 A. Fernández-Serra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. H. Hayes, D. A. Ollendorf, S. D. Pearson et al., “Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis,” Journal of the American Medical Association, vol. 304, no. 21, pp. 2373–2380, 2010.
- A. H. Thomson, S. Kulkarni, and A. Bahl, “Primary cryotherapy with salvage external beam radiotherapy for locally recurrent prostate cancer,” Clinical Oncology, vol. 20, no. 5, p. 385, 2008.
- F. Rabbani, N. Stroumbakis, B. R. Kava, M. S. Cookson, and W. R. Fair, “Incidence and clinical significance of false-negative sextant prostate biopsies,” The Journal of Urology, vol. 159, no. 4, pp. 1247–1250, 1998.
- S. A. Tomlins, D. R. Rhodes, S. Perner et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science, vol. 310, no. 5748, pp. 644–648, 2005.
- S. A. Tomlins, R. Mehra, D. R. Rhodes et al., “TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer,” Cancer Research, vol. 66, no. 7, pp. 3396–3400, 2006.
- S. A. Narod, A. Seth, and R. Nam, “Fusion in the ETS gene family and prostate cancer,” British Journal of Cancer, vol. 99, no. 6, pp. 847–851, 2008.
- S. A. Tomlins, B. Laxman, S. Varambally et al., “Role of the TMPRSS2-ERG gene fusion in prostate cancer,” Neoplasia, vol. 10, no. 2, pp. 177–188, 2008.
- S. A. Tomlins, A. Bjartell, A. M. Chinnaiyan et al., “ETS gene fusions in prostate cancer: from discovery to daily clinical practice,” European Urology, vol. 56, no. 2, pp. 275–286, 2009.
- A. Fernández-Serra, J. Rubio-Briones, Z. García-Casado, E. Solsona, and J. A. López-Guerrero, “Prostate cancer: the revolution of the fusion genes,” Actas Urologicas Espanolas, vol. 35, no. 7, pp. 420–428, 2011.
- Q. P. Sun, L. Y. Li, Z. Chen et al., “Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study,” Journal of Molecular Diagnostics, vol. 12, no. 5, pp. 718–724, 2010.
- M. Yoshimoto, J. C. Cutz, P. A. S. Nuin et al., “Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias,” Cancer Genetics and Cytogenetics, vol. 169, no. 2, pp. 128–137, 2006.
- G. Attard, J. Clark, L. Ambroisine et al., “Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer,” Oncogene, vol. 27, no. 3, pp. 253–263, 2008.
- G. Attard, J. Clark, L. Ambroisine et al., “Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer,” British Journal of Cancer, vol. 99, no. 2, pp. 314–320, 2008.
- S. Perner, F. Demichelis, R. Beroukhim et al., “TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer,” Cancer Research, vol. 66, no. 17, pp. 8337–8341, 2006.
- B. Lu, B. Maqsodi, W. Yang et al., “Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA,” Urology, vol. 74, no. 5, pp. 1156–1161, 2009.
- M. Yoshimoto, A. M. Joshua, S. Chilton-MacNeill et al., “Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement,” Neoplasia, vol. 8, no. 6, pp. 465–469, 2006.
- F. Demichelis, K. Fall, S. Perner et al., “TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort,” Oncogene, vol. 26, no. 31, pp. 4596–4599, 2007.
- J. Rubio-Briones, A. Fernández-Serra, A. Calatrava et al., “Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy,” The Journal of Urology, vol. 183, no. 5, pp. 2054–2061, 2010.
- B. Djavan, M. Remzi, C. C. Schulman, M. Marberger, and A. R. Zlotta, “Repeat prostate biopsy: who, how and when? A review,” European Urology, vol. 42, no. 2, pp. 93–103, 2002.
- J. M. Mosquera, S. Perner, E. M. Genega et al., “Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications,” Clinical Cancer Research, vol. 14, no. 11, pp. 3380–3385, 2008.
- J. J. Tu, S. Rohan, J. Kao, N. Kitabayashi, S. Mathew, and Y. T. Chen, “Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues,” Modern Pathology, vol. 20, no. 9, pp. 921–928, 2007.
- M. Yoshimoto, A. M. Joshua, I. W. Cunha et al., “Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome,” Modern Pathology, vol. 21, no. 12, pp. 1451–1460, 2008.
- D. Pflueger, D. S. Rickman, A. Sboner et al., “N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer,” Neoplasia, vol. 11, no. 8, pp. 804–811, 2009.
- B. Han, R. Mehra, S. M. Dhanasekaran et al., “A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer,” Cancer Research, vol. 68, no. 18, pp. 7629–7637, 2008.
- M. J. Soller, M. Isaksson, P. Elfving, W. Soller, R. Lundgren, and I. Panagopoulos, “Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer,” Genes Chromosomes and Cancer, vol. 45, no. 7, pp. 717–719, 2006.
- S. A. Tomlins, R. Mehra, D. R. Rhodes et al., “Integrative molecular concept modeling of prostate cancer progression,” Nature Genetics, vol. 39, no. 1, pp. 41–51, 2007.
- I. Machado, R. Noguera, A. Pellin et al., “Molecular diagnosis of ewing sarcoma family of tumors: a comparative analysis of 560 cases with fish and rt-pcr,” Diagnostic Molecular Pathology, vol. 18, no. 4, pp. 189–199, 2009.
- R. Salgado, B. Llombart, R. M. Pujol et al., “Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies,” Genes Chromosomes and Cancer, vol. 50, no. 7, pp. 510–517, 2011.
- K. G. Hermans, J. L. Boormans, D. Gasi et al., “Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer,” Clinical Cancer Research, vol. 15, no. 20, pp. 6398–6403, 2009.
- J. Wang, Y. Cai, C. Ren, and M. Ittmann, “Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer,” Cancer Research, vol. 66, no. 17, pp. 8347–8351, 2006.
- R. S. Bridge, V. Rajaram, L. P. Dehner, J. D. Pfeifer, and A. Perry, “Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors,” Modern Pathology, vol. 19, no. 1, pp. 1–8, 2006.
- T. B. Lewis, C. M. Coffin, and P. S. Bernard, “Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues,” Modern Pathology, vol. 20, no. 3, pp. 397–404, 2007.
- M. L. Wallander, K. B. Geiersbach, S. R. Tripp, and L. J. Layfield, “Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing,” Archives of Pathology & Laboratory Medicine, vol. 136, no. 7, pp. 796–803, 2012.
- L. Dvorak, M. Dolan, J. Fink, L. Varghese, J. Henriksen, and H. E. Gulbahce, “Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test,” Applied Immunohistochemistry & Molecular Morphology, vol. 21, no. 3, pp. 196–199, 2013.
- F. L. Baehner, N. Achacoso, T. Maddala et al., “Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4300–4306, 2010.
- A. L. Folpe, J. R. Goldblum, B. P. Rubin et al., “Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases,” American Journal of Surgical Pathology, vol. 29, no. 8, pp. 1025–1033, 2005.
- S. Kumar, S. Pack, D. Kumar et al., “Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue,” Human Pathology, vol. 30, no. 3, pp. 324–330, 1999.
- M. K. Fritsch, J. A. Bridge, A. E. Schuster, E. J. Perlman, and P. Argani, “Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue,” Pediatric and Developmental Pathology, vol. 6, no. 1, pp. 43–53, 2003.
- O. R. Saramäki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. J. Tammela, and T. Visakorpi, “TMPRSS2.ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis,” Clinical Cancer Research, vol. 14, no. 11, pp. 3395–3400, 2008.
- G. Petrovics, A. Liu, S. Shaheduzzaman et al., “Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome,” Oncogene, vol. 24, no. 23, pp. 3847–3852, 2005.
- A. B. Rajput, M. A. Miller, A. de Luca et al., “Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers,” Journal of Clinical Pathology, vol. 60, no. 11, pp. 1238–1243, 2007.
- A. Gopalan, M. A. Leversha, J. M. Satagopan et al., “TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy,” Cancer Research, vol. 69, no. 4, pp. 1400–1406, 2009.
- S. A. Tomlins, S. M. Aubin, J. Siddiqui et al., “Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA,” Science Translational Medicine, vol. 3, no. 94, Article ID 94ra72, 2011.